Condition
ACL Injury: Options and What the Evidence Actually Shows
ACL tears are primarily a surgical and rehab story. Regenerative injectates are adjuncts at best — not a reconstruction substitute.
Anatomy and clinical context
The ACL stabilizes anterior translation and rotation. Complete tears in active patients often lead to reconstruction; some copers do well nonoperatively with bracing and rehab.
Graft choice, timing, and rehab quality drive outcomes more than any injectate marketed around the injury.
Illustration of the human knee joint
The standard-of-care ladder
Conservative care first, then injections, then surgery when indicated. Cell therapy belongs in that conversation — not above it.
- Step 1
Conservative care
Bracing, activity modification, and structured rehab for selected copers.
- Step 2
Injections
Orthobiologics are experimental adjuncts — not standard of care for ACL healing.
- Step 3
Surgery
ACL reconstruction (autograft or allograft) for instability in active patients.
Where cell therapy fits
Do not expect same-day cell therapy to replace ACL reconstruction. Banking is a separate longevity decision, not an ACL treatment plan.
- Reconstruction remains the evidence-based path for most pivoting athletes.
- Adjunct orthobiologics lack strong Level-1 support for ACL healing.
- If you bank cells, it is for future dose elsewhere — not as ACL therapy.
Selected citations
Shapiro 2017
Shapiro et al. · AJSM (2017)
BMAC vs saline in the same patient's other knee — no difference on primary outcomes.
Why dose and donor age change the picture
The trials that disappoint used unexpanded cells from older donors.
The ones that work used expanded cells at therapeutic dose. Dose is the variable — and dose is what expansion buys you. Potency is what your age buys you.
- 1
Cells work at dose.
A same-day draw yields a small, uncounted, unexpanded fraction. Expansion turns one draw into many doses.
- 2
Potency is age-dependent, and it is a one-way door.
Your MSCs at 35 are not your MSCs at 55. Banking is the only mechanism that makes 35-year-old cells available to a 55-year-old.
- 3
Expansion is what makes the bank a supply, not a souvenir.
Bank once, expand repeatedly, across a treatment course rather than a single shot. Culture expansion for Forever Labs members is rolling out — starting with selected states as our Florida cGMP lab comes online.
- 4
The provider decides what happens next.
We supply cells; they practice medicine. Forever Labs does not treat conditions — your physician owns the clinical relationship.
Two next steps — equal weight
Forever Labs does not treat conditions. Your physician owns the clinical relationship. We bank cells and, as expansion rolls out, help make dose possible.